Revenue generated from consultancy projects (excluding Patients consultancy) including Clinical trials (Last five years) S. No. Name of the consultant Name of consultancy/clinical trial project Consulting/Sponsoring Year Revenue agency with contact details generated 1 Dr.J. DAMODHARAN A Randomized, open label, multicentre, comparative clinical trial Lambda Therapeutic 2014 232000 of IN-SUPR-002 in comparison with fixed dose combination (FDC) Research Ltd, Ahmedabad. of fenofibrate and rosuvastatin in patients with mixed Dyslipidemia. 2 Dr.ANITA RAMESH Open label randomized bioequivalence study to evaluate the Cliantha Research Ltd. 2014 1900000 pharmacokinetic (PK) and safety profile of Bevacizumab Biosimilar (BEVZ92) in combination with FOLFOX or FOLFIRI versus Bevacizumab (AVASTIN®) in combination with FOLFOX or FOLFIRI as first-line treatment in patients with metastatic ColoRectal Cancer (mCRC) 3 Dr.S.ANANDAN A Prospective, Open-Label, Multicenter, Randomized, Active- Max Neeman Medical 2014 1430400 Controlled Study to Compare the Efficacy of Alpecin Liquid Anti International Limited. Hair Loss Treatment to Minoxidil 5% Solution in the Management of Androgenetic Alopecia 4 Dr.SHANTHI A multicentric study, to assess the immunogenicity and the PROSPER CHANNEL 2014 300000 VIJAYARAGHAVAN safety of ‘Inactivated Hepatitis A Vaccine (Healive®)’ Lifescience India Pvt. Ltd. administered to healthy adults. 5 Dr. M.Manickavasagam Protocol No.: PEGF/USV/P3/001 A Phase III, Randomized, GVK Biosciences Pvt. Ltd. 2014 70000 Multicentric, Open-label, Equivalence Design Study to Compare the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Patients Receiving Doxorubicin and Docetaxel as a Combination Chemotherapy for Breast Cancer 6 Dr.A.J.HEMAMALINI Effect of Omega 3 fatty acid (Fish Oil / Algal Oil) enriched Tamilnadu Dairy 2014 75000 functional dairy foods on the lipid profile of borderline high Development hyperlipidemic adults. 7 Dr.PADMASANI Rota: 04/vac-020 / a phase III, multicenter, open label, Syngene International Ltd. 2014 1809050 VENKATRAMAN randomized study of bovine rotavirus pentavalent vaccine (BRV- PV) to evaluate lot-to-lot consistency, and to investigate potential interference with routine UIP vaccinations in healthy infants in india. 8 Dr.ANITA RAMESH A Randomised, Multi-centre, Double-blind, Parallel Group Study Dr. Reddy’s Laboratories 2014 1459115 to Compare the Pharmacokinetics, Pharmacodynamics, Safety Ltd., and Efficacy of Two Anti-CD20 Monoclonal Antibodies in Combination with CHOP in Patients with CD20-Positive Diffuse Large B-cell Lymphoma 9 Dr.SATHIANATHAN CN162-010- A Multicentre, Double-Blind, 58 Week Rollover BRISTOL MYERS SQUIBB 2014 1718919 Study to assess the Safety and Tolerability of BMS-820836 in India Private Limited Patients with Treatment Resistant Major Depression 10 Dr.SHANTHI A prospective, multicentre, Observational Study to Profile Max Neeman Medical 2014 144000 VIJAYARAGHAVA Chronic Cholestatic Liver Diseases in Patient Population International Limited. Receiving Udiliv in India – The SPLENDID study. 11 Dr. KRISHNA SESHADRI CLR_10_33 entitled ‘Safety And Efficacy of Exenatide Injection in Sun pharmaceuticals 2014 480000 Subjects with Type 2 Diabetes Mellitus: A Randomized, Double industries Limited Blind, Placebo-Controlled, Parallel Groups, Multicentric, 24- WeekTrial. 12 Dr.ANITA RAMESH International multicenter randomized double blind phase III BIOCAD India Pvt. Ltd. 2014 1650000 clinical trial comparing safety and efficacy of BCD-022 CJSC BIOCAD, Russia) used with paclitaxel to Herceptin® (F. Hoffmann-La Roche Ltd, Switzerland) used with paclitaxel in the first- line treatment of HER2- positive metastatic breast cancer patients. 13 Dr. KRISHNA SESHADRI Trial ID:NN9535-3626: Trial phase:3a: Efficacy and safety of Novo Nordisk India private 2014 1980000 semaglutide once-weekly versus sitagliptin once-daily as add-on Ltd to metformin and/or TZD in subjects with type 2 diabetes. 14 Dr. KRISHNA SESHADRI A Phase III, Multicentre, Randomized, Parallel Group, Double Macrocare Clinical Research 2014 1199600 Blinded and Control Group Clinical Trial to Assess the Limited Effectiveness of Biochaperone PDGF BB in the Treatment of Chronic Diabetic Foot Ulcer.” BCI-CT4 15 Dr.ANITA RAMESH PROTOCOL No.RLS/TP/2011/05 RLS/TP/2011/05; Prospective, Reliance Life Sciences 2014 1519250 multicentre, randomized, open-label, two arm, parallel group, active-control, comparative clinical study to evaluate efficacy, safety and pharmacokinetics of R-TRP-016/ Herceptin® when given intravenously in patients with Metastic HER2- Overexpressing Breast Cancer 16 Dr. S. Anandan “Investigation on Changes In Collagen Content, Skin Thickness Indian Institute of 2015 975400 And Micro Vascularity In Diffuse Systemic Scleroderma Patients Technology Madras Using Bimodal Optical Spectroscopy” 17 Dr. KRISHNA SESHADRI An observational cross sectional study to assess the prevalance TECH OBSERVER INDIA (P) 2015 200000 of chronic kidney disease in Type 2 Diabetes Patientts in India. Ltd START – INDIA 18 Dr.LATHA A Phase IV, Non-inferiority, Observer blind, Randomized clinical Serum Institute of India Ltd. 2015 877500 RAVICHANDRAN study comparing safety and immunogenicity of DTP-HB-Hib vaccination by disposable-syringe jet injector to vaccination by needle and syringe in healthy infants in India 19 Dr.PADMASANI PCV-10-002 “A Phase 2, Prospective, Multi-Center, Randomized, DiagnoSearch Life Sciences 2015 1702500 VENKATRAMAN Two-Arm, Active Controlled, Double-Blind Study to Evaluate the Pvt. Ltd. Safety, Tolerability, and Immunogenicity of Serum Institute of India’s 10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Indian PCV-Naïve Toddlers (12 to 15 months).” 20 Dr.USHA VISHWANATH DIS-2014-009 DIS-2014-009 – International Observational E- Medicem International 2015 250000 Registry on the use of Dilapan-S / Dilasoft osmotic dilators for Gmbh cervical ripening prior to induction of labour 21 Dr.RADHA ANNAMALAI Protocol No: PSV-FAI-005 “A Multi-center, Controlled, Safety and Excel Life Science 2015 702500 Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye.” 22 Dr.PADMASANI MMR-01/123. Protocol No: "A Phase III Multicentric Randomized Serum Institute of India Ltd. 2015 393750 VENKATRAMAN Single Blind Study To Compare The Immunogenicity And Safety Of HBI Pentavalent (DTWP-HB-HIB[LIQUID]) Combination Vaccine With Pentavac Sd® Vaccine When Administered In Three Doses To 6-8 Weeks Old Healthy Infants." 23 Dr. K.S Rajeswari A Randomized, single blind, multi-centre, parallel-arm, pilot scale Accutest Research 2015 340000 study to ascertain the efficacy of coated Copper T in reducing Laboratories (I) Pvt.Ltd. bleeding side effects as Compared with Copper T 380 A for a maximum of 1 year. 24 Dr. N. Sanjeeva Reddy Protocol No.: BSV_rhFSH_15_01 A randomized, multicentre, SIRO Clinpharm 2015 1579440 parallel-group, assessor-blind Phase III study to compare the efficacy and safety of Foligraf™ and Gonal-F® in subjects undergoing controlled ovarian stimulation for ART. 25 Dr. Saji James Protocol No: "A Phase III Multicentric Randomized Single Blind PENTAVAC SD 2015 520000 Study To Compare The Immunogenicity And Safety Of HBI Pentavalent (DTWP-HB-HIB[LIQUID]) Combination Vaccine With Pentavac Sd® Vaccine When Administered In Three Doses To 6-8 Weeks Old Healthy Infants." 26 Dr.PADMASANI MMR-01/123. Protocol No: "A Phase IV,Interventional, open Bharat Immunological and 2015 755000 VENKATRAMAN label, multicentric, single arm clinical trial to assess the safety, biological corporation Ltd tolerability & immunogenicity of bivalent oral polio vaccine (bOPV) in healthy Indian infants. 27 Dr. R.B. Sudagar Singh Protocol No: Ipca/HCQS/PIV-14: Evaluation of Safety andEfficacy Ipca Labor atories Ltd. 2015 300250 of Hydroxychloroquine Sulfate as an Adjunct to Diet and Exercise to Improve Glycemic Control in Type 2 Diabetes Patients Uncontrolled on Sulfonylurea + Metformin Combination. 28 Dr.Padmasani Comparative evaluation of immunogenicity of bivalent oral Panacea Biotech Ltd 2015 2300000 poliovirus vaccine (bOPV) schedule with a dose of inactivated polio vaccine (IPV) at week 14 and assessment of immunogenicity of IPV only schedule in the EPI: A multicentric open label randomized controlled trial. 29 Dr. Binu Nainan Thermoregulation of stable low birth weight babies in a low cost IIT – Madras & Maryland 2016 898806 incubator- A pilot study university 30 Dr.RADHA ANNAMALAI Protocol No: A Clinical Study to evaluate the Efficacy, Safety and Taiyo Clinical Research 2016 240000 Tolerability of Brinzolamide1.0% w/v Brimonidine Tartrate 0.2% w/v ophthalmic suspension Vs Brinzolamide 1% Eye drops in patients with open-angle Glaucoma or Ocular Hypertension. 31 Dr.R. RadhaKrishnan VB071/2014-CTI – Safety and efficacy of dexadine (cadexomer Virchow BioTech Pvt Ltd 2016 310500 iodine) in the treatment of chronic wounds. 32 Dr. S. Anandan Protocol No: 228-14 “A Randomized, Double-Blind, Placebo- Lambda Therapeutic 2016 480000 Controlled, Three-Arm, Parallel Group, Multi-Centric, Clinical Research Study To Evaluate The Therapeutic Bio-Equivalence Of Two Tacrolimus 0.03% Topical Ointment Formulations In Adult Patients With Moderate To Severe Atopic Dermatitis”. 33 Dr.R.B.Sudagar Singh OAHT SCPFC-001 “A randomized, single centre, double-blind, Omni Active Health Tech 2016 2300000 parallel group, Placebo controlled, Two Arm, Comparative, Interventional